This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Eli Lilly and Company. Active years: 2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009
Title: Rainer Riedl: Innovator in Glucokinase Activators
Introduction
Rainer Riedl is a notable inventor based in Norderstedt, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of glucokinase activators. His work is characterized by a commitment to innovation and scientific advancement.
Latest Patents
Riedl holds a patent for "Substituted arylcyclopropylacetamides as glucokinase activators." This invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. This patent highlights his expertise in creating novel compounds that can potentially enhance glucose metabolism.
Career Highlights
Rainer Riedl is currently associated with Eli Lilly and Company, a leading global pharmaceutical company. His role at Eli Lilly allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies.
Collaborations
Throughout his career, Riedl has collaborated with esteemed colleagues, including Andreas Gerhard Weichert and David Gene Barrett. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.
Conclusion
Rainer Riedl's contributions to the field of glucokinase activators exemplify his dedication to innovation in pharmaceuticals. His work continues to influence the development of new therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile